Champions Oncology (NASDAQ:CSBR – Get Free Report) and OmniAb (NASDAQ:OABI – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership and earnings.
Insider and Institutional Ownership
41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 72.1% of OmniAb shares are held by institutional investors. 47.0% of Champions Oncology shares are held by company insiders. Comparatively, 9.8% of OmniAb shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Risk & Volatility
Champions Oncology has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500. Comparatively, OmniAb has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Champions Oncology | -1.87% | -27.48% | -3.84% |
| OmniAb | -115.12% | -16.59% | -14.82% |
Valuation & Earnings
This table compares Champions Oncology and OmniAb”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Champions Oncology | $59.42 million | 1.16 | -$1.17 million | ($0.08) | -62.04 |
| OmniAb | $18.67 million | 36.52 | -$64.78 million | ($0.36) | -13.08 |
Champions Oncology has higher revenue and earnings than OmniAb. Champions Oncology is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Champions Oncology and OmniAb, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Champions Oncology | 1 | 0 | 0 | 0 | 1.00 |
| OmniAb | 1 | 0 | 2 | 0 | 2.33 |
OmniAb has a consensus target price of $11.00, indicating a potential upside of 133.55%. Given OmniAb’s stronger consensus rating and higher probable upside, analysts clearly believe OmniAb is more favorable than Champions Oncology.
Summary
OmniAb beats Champions Oncology on 8 of the 14 factors compared between the two stocks.
About Champions Oncology
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
About OmniAb
OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
